Market Signal Briefing

Bitcoin's (CRYPTO: BTC) breakout remains structurally strong and well-supported, though Glassnode data indicates the market is transitioning into a more mature phase.

What Happened: According to Glassnode, rising leverage and measured profit-taking could inject near-term fragility, even as the broader uptrend remains fundamentally strong.

Bitcoin's rally across spot and futures markets is being fuelled by over $2.2 billion in ETF inflows, one of the strongest surges since April, alongside rising spot volumes and renewed institutional demand.

However, leverage has climbed sharply, with open interest hitting record highs and funding rates surpassing 8%, indicating the potential for short-term volatility or shakeouts.

In the options market, sentiment has shifted decisively bullish: implied volatility is up, skew has normalized, and traders are increasingly favouring call-heavy positions.

Yet this optimism has driven up the cost of upside exposure, creating a more crowded and volatile setup as the market juggles enthusiasm with leverage risk.

Also Read: Bitcoin Could Reach $150,000 If Q4 Seasonality Delivers, Trader Says

Why It Matters: Bitcoin has climbed to a new all-time high near $126,000, breaking through strong resistance between $114,000–$117,000 and highlighting renewed market strength.

On-chain metrics reveal robust accumulation by small-to-mid-sized holders (10–1,000 BTC), while whale selling has eased, signaling healthier, more organic demand.

This buying activity provides structural support around $117,000–$120,000, where 190,000 BTC last changed hands, marking a potential rebound zone if prices pull back.

Profit-taking has increased slightly but remains measured, consistent with a sustainable bullish phase rather than a market top.

Read Next:

Bitcoin Holds Near $122,000 On Sentiment Shift, Ethereum, XRP, Dogecoin Slide
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The rollout includes new bitcoin payment tools and a merchant wallet aimed at making cryptocurrency use easier for small businesses.

Darius Baruo
Oct 08, 2025 19:44

Gala Games introduces its first cross-world event in Townstar, offering unique NFT rewards and GALA tokens. The event runs from October 14 to 17, 2025.

The spirits of the Gala universe are awakening as Gala Games announces an unprecedented cross-world event starting with Townstar. This event marks a significant milestone for the gaming platform, inviting players to engage in a multi-game adventure with enticing rewards, according to Gala News.

Event Details and Rewards
Players are challenged to demonstrate their prowess in lemonade production during the haunted Townstar challenge. The event is set to run from October 14 to 17, 2025, offering participants the opportunity to earn more than just GALA tokens. The top 225 players on the leaderboard will receive an exclusive NFT, the "VEXI Scaremel (Epic)." This limited-edition NFT offers unique advantages such as affinity with the Candy Cart (Small) and 30 event points in VEXI Villages.

Exclusive NFT: VEXI Scaremel (Epic)
The "VEXI Scaremel (Epic)" NFT is described as a sugary spirit born from caramel and chaos, adding a deliciously dark charm to the player's inventory. It is designed for explorers with a penchant for adventure and a sweet tooth, enhancing the gaming experience with its unique attributes.

Continuing the Adventure
The Halloween-themed journey does not end with Townstar. Following the initial event, players can continue their adventure in VEXI Villages from October 23 to 27, 2025. This continuation promises to expand the storyline and offer further opportunities for gamers to engage with the Gala universe.

Gala Games' innovative approach with this cross-world event highlights its commitment to enhancing player experience and engagement through unique, multi-dimensional gaming opportunities.

Image source: Shutterstock

gala games
nft
townstar

The U.S. is poised to step into the institutional cryptocurrency arena in a historic way. Senator Cynthia Lummis, a well-known advocate for digital assets, recently confirmed that the United States government is prepared to begin funding its Strategic Bitcoin Reserve (SBR) at any moment.

Coinbase has activated staking services for New York residents allowing yields on Ethereum and Solana holdings after state regulatory approval, while users in California, New Jersey, Maryland, and Wisconsin collectively miss over $130 million in rewards from ongoing restrictions.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bloomberg analyst Eric Balchunas has highlighted how the BlackRock Bitcoin ETF (IBIT) has performed in comparison to the world’s largest asset manager’s older funds. This comes as the fund approaches the $100 billion milestone, which will make it the fastest to reach this milestone. 

BlackRock Bitcoin ETF Becomes Most Profitable Fund
In an X post, Balchunas revealed that the BlackRock Bitcoin ETF, which is approaching $100 billion, is now the most profitable fund for the asset manager by a “good amount.” The Bloomberg analyst also highlighted that this is a massive feat for the Bitcoin fund, considering its age in comparison to the other funds.  

The BlackRock Bitcoin ETF, which was launched last year, is currently generating an annual revenue of $244.5 million for the world’s largest asset manager. This is well ahead of BlackRock’s Russell 1000 Growth ETF, which is 25 years old and generates an annual revenue of $219.3 million, placing it in second place. 

Notably, the BlackRock Bitcoin ETF is the only fund on the list that has a single-digit age. The other of BlackRock’s funds are 12 years and above. Eric Balchunas also noted that IBIT was approaching $100 billion in assets under management (AuM), which could make it the fastest to reach this milestone. 

Source: Chart from Eric Balchunas on X
The Bloomberg analyst revealed that the Vanguard S&P 500 ETF currently holds this record, although it achieved this feat in 2,011 days. Meanwhile, the BlackRock Bitcoin ETF, which is just 437 days old, currently has $99.44 billion in assets under management, putting it on track to surpass this record by a considerable margin.

This comes as the BlackRock BTC ETF continues to lead the pack, with massive daily net inflows. On October 6, these Bitcoin funds saw $1.19 billion in daily net inflows, with IBIT accounting $970 million of these flows. Meanwhile, they recorded a daily net inflow of $875.6 million yesterday, with IBIT accounting for $899.4 million of these flows. 

IBIT Also Among Top 20 ETFs By AuM
Eric Balchunas also revealed that the BlackRock Bitcoin ETF is now in the top 20 in ETF assets following the rapid increase in its AuM. Based on its current AuM, IBIT is 19th on the list of largest ETFs, just ahead of Vanguard’s VIG and the “legendary” Technology Select Sector SPDR Fund. 

The Bloomberg analyst remarked that if the last 12 months are repeated, it may not take too long for the BlackRock Bitcoin ETF to break into the top 10. He noted that the fund took in $40 billion over the last 12 months and saw an 85% increase. He added that he will put the timeline at December 2026 if he has to give one. 

At the time of writing, the BTC price is trading at around $121,500, down over 2% in the last 24 hours, according to data from CoinMarketCap.

BTC trading at $121,899 on the 1D chart | Source: BTCUSDT on Tradingview.com
Featured image from Getty Images, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts.
Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

Saint-Petersburg Exchange (SPB), a major stock market in Russia, is now hosting futures trading for contracts based on the value of Bitcoin and BRICS assets. The exchange began preparations to provide the service right after the Bank of Russia authorized the offering of crypto derivatives to qualified investors this past spring.

Martinez acknowledges that the $2.82 range has proven a strong support for XRP, with buyers consistently stepping in to prevent deeper declines.

Cryptocurrency markets are climbing as Bitcoin's uptrend resumes, fueled by corporate BTC purchases and increased demand for U.S. spot Bitcoin ETFs.

CryptocurrencyTickerPriceBitcoin(CRYPTO: BTC)$123,519.26Ethereum(CRYPTO: ETH)$4,519.30Solana(CRYPTO: SOL)$227.06XRP(CRYPTO: XRP)$2.90Dogecoin(CRYPTO: DOGE)$0.2583Shiba Inu(CRYPTO: SHIB)$0.00001236Notable Statistics:

Coinglass data shows 129,160 traders were liquidated in the past 24 hours for $399.13 million.       
In the past 24 hours, top gainers include Zcash (CRYPTO: ZEC), Mantle (CRYPTO: MNT) and SPX6900 (CRYPTO: SPX).
Notable Developments:

Ethereum Is Stuck Below $4,500 Until This Key Indicator Catches Up, Analyst Says
‘Asia’s MSTR’ Metaplanet Meets Chart Level That Could Make Or Break It
ETH And Bit Digital’s BTBT Just Aligned — $5,000 ETH And $5 BTBT Could Be Next
DOGE And SHIB Are Done — BONK’s Chart Points To A 400% Moonshot
North Korean Hackers Set A Record With $2 Billion Crypto Heist in 2025: Report
Bitcoin Rebounds Above $122,000—But For ETH, XRP That May Be Bad News
Trader Notes: Castillo Trading highlighted that Bitcoin is showing a healthy bounce, with dips becoming shallower and increasingly difficult to catch.

This suggests strong momentum and the potential for continued upward movement, even though $120,000 bids remain unfilled.

Trader Tim noted that Bitcoin's recent close was weak, raising caution.

A strong weekly close could alleviate concerns, and altcoins might still catch longs, but for now, warning signs remain.

No top is being called, yet the outlook is not entirely clear.

Satoshi Stacker observed that overly aggressive bearish positions at recent lows triggered short liquidations, which are now fueling Bitcoin's rally.

Daan Crypto Trades commented that Bitcoin is demonstrating strong early October momentum.

Although the month still has a long way to go, Q4 is starting off well.

A gradual pace would help sustain the trend rather than risk an unsustainable spike.

IncomeSharks pointed out that Bitcoin continues to follow the expected pattern, while yesterday's small red candle led to unnecessary bearish posts that didn't reflect the market's true direction.

Read Next:

Bitcoin To $200,000 In 2025 Is Still In Play, Bitwise’s Matt Hougan Says
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Ethena Labs, the team behind the synthetic dollar USDe, has partnered with Jupiter Exchange, a decentralized exchange (DEX) aggregator on Solana, to introduce JupUSD, a new native stablecoin designed for the Jupiter ecosystem.

Controversial Bitcoin developer Luke Dashjr claims that he is tired of personally saving Bitcoin "every few years."   

"Even if we survive this attack by Core30, this situation, where I personally have to save Bitcoin every few years, needs to stop," Dashjr said in a recent social media post. 

According to Dashjr, Bitcoin will not be able to survive if it relies just on one man, so other developes need to step up. 

HOT Stories

Has Dashjr actually saved Bitcoin?  Despite his fringe and extreme ideological views, Dashjr is often credited with "saving" Bitcoin on numerous occasions.  

In 2013, he was part of the emergency group of developers who quickly fixed the inflation bug that caused a chain split between nodes and was close to eroding confidence in the original cryptocurrency.

You Might Also Like

Dashjr was also a loud opponent of the "SegWit2x" hard fork that was supposed to double the block size of the leading cryptocurrency. Despite being pushed by major mining companies and exchanges, the hard fork ultimately failed.

He also opposed Ordinals and inscriptions in order to prevent a UTXO blot. Dashjr claims that he tried to fix the issue before there was a huge spike in unspent outputs, but he was recovering from a hack back then. 

Most recent controversy As reported by U.Today, Dashjr was recently embroiled in yet another controversy, with leaked messages allegedly showing his plan to launch a hard fork in order to retroactively modify the blockchain with the help of a trusted multisig committee. 

The maintainer of the Bitcoin Knots client has clashed with Bitcoin Core developers over the decision to remove the default limit on OP_RETURN data. Dashjr, a staunch conservative, is an extremely loud opponent of lifting the limit.   

In response to backlash, Dashjr dismissed the published messages as "fabricated nonsense."

XRP (CRYPTO: XRP) is drawing fresh attention after Cardano (CRYPTO: ADA) founder Charles Hoskinson highlighted its untapped potential in decentralized finance, saying nearly $100 billion worth of idle XRP could soon enter yield-bearing ecosystems. 

The remarks came just as Nasdaq-listed Reliance Global Group Inc. (NASDAQ:RELI) announced it has added XRP to its corporate digital asset treasury.

Hoskinson Sees $100B XRP Unlocking DeFi LiquiditySpeaking during a livestream, Hoskinson said the XRP community has "almost a hundred billion dollars of XRP floating around that's yield-free," suggesting that regulatory clarity and real-world asset (RWA) integration could transform XRP into a major DeFi liquidity source.

"You try to match RWAs and all these emerging assets that now, because of changing regulation, can finally enter the space," Hoskinson said. 

"You pair them up with Bitcoin, ADA, XRP and that alone could get us $10–15 billion in TVL and a lot more transaction volume."

His comments underscore how DeFi protocols are beginning to explore interoperability with non-EVM blockchains.

Nasdaq-Listed Reliance Adds XRP To TreasuryReliance Global confirmed on Sep. 30 that it completed a purchase of XRP as part of its Digital Asset Treasury (DAT) strategy, joining its existing holdings of Bitcoin (CRYPTO: BTC), Ethereum (CRYPTO: ETH), and Cardano (CRYPTO: ADA). 

The company cited XRP's efficiency as the reason for inclusion, calling it a "measured step" toward diversified blockchain exposure.

CEO Ezra Beyman said the firm aims to build a balanced digital portfolio reflecting both innovation and long-term shareholder value. 

XRP Price Consolidates Ahead Of Breakout

XRP Breakout Analysis (Source: TradingView)

Technical analysis: XRP is trading near $2.91, consolidating inside a symmetrical triangle formation. 

Resistance remains capped at $2.93, where the 20-day EMA coincides with the upper boundary of the pattern. 

Immediate support rests at $2.85, followed by $2.74.

The Bollinger Bands are tightening, indicating reduced volatility that often precedes strong directional moves. 

A daily close above $2.93 could open the way toward $3.07, while failure to hold support may trigger a slide to $2.64.

Why It MattersXRP is rarely discussed as a DeFi engine, yet Hoskinson's $100 billion liquidity framing flips that narrative on its head.

If even a fraction of that idle supply migrates into yield markets, the impact on DeFi's total value locked could be seismic.

The timing alongside Reliance's Nasdaq-listed treasury move gives the narrative a rare blend of grassroots and institutional backing.

Such alignment hints at XRP's next frontier — not just payments or remittances, but deep integration with on-chain capital markets.

For traders, it raises the question of whether XRP is shifting from a transactional token into a structural pillar of DeFi itself.

Read Next:

Bitcoin Could 10x From Here, Says PayPal’s Ex-Boss—And This Pricing Model Agrees
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

PHILADELPHIA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Axalta Coating Systems Ltd. (NYSE: AXTA), a leading global coatings company, will release its third quarter 2025 financial results at 6 a.m. ET on Tuesday, October 28. The release and supporting materials will be posted to Axalta’s Investor Relations site.

In addition, the company will host a conference call at 8 a.m. ET on October 28. Chris Villavarayan, Chief Executive Officer and President, and Carl Anderson, Senior Vice President and Chief Financial Officer, will review the company's financial performance for the period. A live webcast of the conference call will be available here. A replay of the webcast will be posted shortly after the call and will remain accessible through October 28, 2026.

The dial-in phone number for the conference call is 1-800-245-3047 and the conference ID is AXALTA. For those unable to participate, a replay of the call will be available through November 4, 2025. The replay dial-in number is 1-844-512-2921. The replay passcode is 11160096.

About Axalta

Axalta is a global leader in the coatings industry, providing customers with innovative, colorful, beautiful and sustainable coatings solutions. From light vehicles, commercial vehicles and refinish applications to electric motors, building facades and other industrial applications, our coatings are designed to prevent corrosion, increase productivity and enhance durability. With more than 150 years of experience in the coatings industry, the global team at Axalta continues to find ways to serve our more than 100,000 customers in over 140 countries better every day with the finest coatings, application systems and technology. For more information visit axalta.com and follow us on LinkedIn.

October 08, 2025 2:30 PM EDT | Source: Railtown AI Technologies Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2025) - Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF) ("Railtown" or the "Company"), a leader in AI Agentic Frameworks and Observability tools, is thrilled to announce a Memorandum of Understanding (MOU) with Uniserve Communications Corporation (TSXV: USS) ("Uniserve"), a provider of managed IT, cloud, and data centre services with a 30-year operating history and over 10,000 businesses served. This strategic partnership positions Railtown to deliver its cutting-edge AI solutions to Uniserve's extensive network of approximately 3,000 small and medium-sized enterprise (SME) customers, significantly expanding Railtown's market reach and impact.

Partnership Overview

The collaboration integrates Railtown's advanced AI Agentic Frameworks and Observability tools with Uniserve's robust infrastructure, comprised of Data Centre solutions, ISP services, and Managed IT Services. This partnership enables Railtown to deploy scalable, cost-effective AI solutions tailored for SMEs, addressing the growing demand for modernization through the incorporation of AI agentic tools to maintain competitive relevance in a rapidly changing global marketplace.

Uniserve plans to increase its GPU compute capacity as its existing customer base begins the adoption of these types of agentic solutions in their day-to-day business operations.

By accessing Uniserve's established SME client base and national infrastructure, Railtown can rapidly scale and deploy its AI tools, empowering Canadian businesses to enhance their efficiency and competitiveness by providing them the foundational elements to build and deploy Agentic AI into their workflows and product offerings.

This partnership unlocks significant growth opportunities for Railtown by providing access to a market segment of Canadian businesses that are facilitated through Uniserve's management services. Railtown's AI tools will enable Uniserve's SME clients to implement modernization strategies, driving operational improvements and deepening Railtown's position as a key player in Canada's AI ecosystem.

Strategic Benefits for Railtown

Expanded Market Access: Railtown gains direct access to Uniserve's 3,000 SME customers, amplifying the reach of its AI Agentic Frameworks and Observability tools. Scalable Deployment: Uniserve's infrastructure supports the rapid deployment of Railtown's AI solutions tailored to SME needs. Revenue Growth Potential: This partnership is a further addition to Railtown's strategy of developing and growing its compute centric revenue pipeline. Strengthened Market Position: Collaborating with Uniserve reinforces Railtown's leadership in delivering practical AI solutions, enhancing its reputation as a trusted partner for Canadian businesses.Driving SME Innovation

By combining Railtown's AI expertise with Uniserve's established infrastructure and client relationships, the partnership is poised to deliver transformative AI solutions that address the unique needs of SMEs. These solutions will help businesses streamline operations, improve margins, and compete more effectively in a rapidly evolving market.

Cory Brandolini, CEO of Railtown, stated: "Partnering with Uniserve is a meaningful step forward in bringing accessibility to our AI Agentic Frameworks and Observability tools to the vast long tail SME audience. This collaboration not only accelerates the adoption of our technology but also positions Railtown's products to be a key technical layer at the forefront of driving AI compute resources and part of Canada's AI innovation ecosystem. Shared compute revenue streams will vastly out preform traditional SAAS models."

Kwin Grauer, Chairman and Interim CEO of Uniserve, added: "Railtown's AI solutions enable us to enhance our service offerings and deliver cutting-edge technology to our SME customers, meeting the growing demand for AI-driven modernization. This will also serve as a natural kickoff point to build our GPU compute capacity to serve the growing need among our customers for these types of solutions for their business needs."

About Railtown AI Technologies Inc.

Railtown develops AI Agentic Frameworks and Observability tools designed to empower businesses to build, deploy, and manage AI solutions efficiently, driving innovation and growth.

About Uniserve Communications Corporation

Uniserve (TSXV: USS) provides IT solutions, including Data Centre Solutions, Managed IT Services, and Business Internet, through its offices in Vancouver, Calgary, and Waterloo, serving approximately 3,000 SME customers. 

Follow us on social media

LinkedIn: https://www.linkedin.com/company/railtown-ai/ SUBSCRIBE FOR INVESTOR NEWS

Click here to receive our latest investor news alerts.

ON BEHALF OF THE BOARD

"Cory Brandolini"
Cory Brandolini, Chief Executive Officer

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will," "may", "should", "intends", "anticipates", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, the commencement of trading of the Company's common shares on the CSE, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269680

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trial 

Libtayo is the current standard of care in advanced CSCC; approval has the potential to change the treatment paradigm for patients in an earlier setting

TARRYTOWN, N.Y., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. The FDA evaluated Libtayo under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions. An additional regulatory application is also under review in the European Union, with a decision expected by the first half of 2026.

"Patients whose CSCC is at a high risk of recurrence following surgery and radiation often have the poorest outcomes. Until now, we lacked options to help prevent a devastating recurrence and immunotherapy was only available for patients with advanced CSCC who were no longer candidates for curative surgery or curative radiation,” said Vishal A. Patel, M.D., Associate Professor of Dermatology and of Medicine (Hematology/Oncology), George Washington University School of Medicine & Health Sciences and Director, Cutaneous Oncology Program, GW Cancer Center. “Many patients who undergo surgical resection of their CSCC are later found, on full pathological evaluation, to be at high risk of recurrence. As the first and only immunotherapy approved in the adjuvant setting, Libtayo represents a practice-changing opportunity for this patient population, backed by compelling data showcasing its ability to significantly improve disease-free survival.”

The FDA approval is based on data from the pivotal Phase 3 C-POST trial investigating adjuvant Libtayo versus placebo in patients with CSCC at high risk of recurrence after surgery and radiation. Results from the study, which were published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting earlier this year, showed that Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death compared to placebo in patients with CSCC at high risk of recurrence after surgery and radiation (hazard ratio [HR]: 0.32; 95% confidence interval [CI]: 0.20-0.51; p<0.0001).

The safety profile of Libtayo as adjuvant treatment of patients with CSCC at high risk of recurrence after surgery and radiation is consistent with the known safety profile for Libtayo monotherapy in advanced cancers. The most common adverse reactions as a single agent in adjuvant CSCC at high risk of recurrence (≥10%, with a difference between arms of ≥3% compared to placebo) were rash, pruritus, and hypothyroidism. Serious adverse reactions occurred in 18% of patients and those that occurred in ≥1% of patients in the Libtayo arm were pneumonia (1.5%), rash (1.5%), diarrhea (1.5%), adrenal insufficiency (1%), and arrhythmia (1%).

“This approval provides patients with CSCC at high risk of disease recurrence following surgery and radiation a much-needed option, as Libtayo is the only immunotherapy to demonstrate efficacy in this setting,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron. “Now with five FDA-approved indications, Libtayo is firmly established as a strong and versatile PD-1 inhibitor option for patients with a variety of cancers.”

“CSCC is one of the most common skin cancers in the world, with an estimated 1.8 million cases diagnosed each year in the U.S. alone. While it can often be treated successfully with surgery and radiation, many patients face serious risk of advanced disease recurrences,” said Samantha R. Guild, President, AIM at Skin Cancer Foundation. “This approval is wonderful news for people living with CSCC, and we commend Regeneron for its long-standing commitment to addressing needs in non-melanoma skin cancer through its pioneering research.”

Regeneron is committed to helping patients who have been prescribed Libtayo access their medication. The company has launched Libtayo Surround™, which offers financial and educational resources to help support patients throughout their treatment journey. For more information, patients can call 1-877-LIBTAYO (1-877-542-8296).

The approved supplemental Biologics License Application (sBLA) did not include Catalent Indiana, LLC as a filling site.

About Regeneron in Cancer
We aspire to turn revolutionary discoveries into medicines that can transform the lives of those impacted by cancer. Our team around the world is driven to solve the needs and challenges of those affected by one of the most serious diseases of our time.

Backed by our legacy of scientific innovation and a deep understanding of biology, genetics and the immune system, we’re pursuing potential therapies across more than 30 types of solid tumors and blood cancers. Our cancer strategy is powered by cutting-edge technologies and therapies that can be flexibly combined to investigate potentially transformative treatments for patients. Oncology assets in clinical development comprise nearly half of Regeneron’s pipeline, and include checkpoint inhibitors, bispecific antibodies and costimulatory bispecific antibodies. Our approved PD-1 inhibitor Libtayo serves as the backbone of many of our investigational combinations.

To complement our extensive in-house capabilities, we collaborate with patients, healthcare providers, governments, biopharma companies and each other to further our shared goals. Together, we are united in the mission to serve as a beacon of transformation in cancer care.

About Libtayo  
Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), CSCC that is advanced or at high risk of recurrence, advanced non-small cell lung cancer (NSCLC) and advanced cervical cancer.

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. FDA. Outside of the U.S., the generic name of Libtayo in its approved indications is cemiplimab.   

The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either conventional or novel therapeutic approaches for other solid tumors and blood cancers. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.

U.S. FDA-approved Indications   
Libtayo is a prescription medicine used to treat:  

Adults with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC): that has spread or cannot be cured by surgery or radiation, orto help prevent CSCC from coming back if your CSCC is at high risk of coming back after it has been removed by surgery and radiation. Adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI.  Adults with a type of lung cancer called non-small cell lung cancer (NSCLC). LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene.LIBTAYO may be used alone as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high “PD-L1,” and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene.
It is not known if Libtayo is safe and effective in children.   

IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS 

What is the most important information I should know about LIBTAYO?
LIBTAYO is a medicine that may treat certain cancers by working with your immune system. LIBTAYO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

Lung problems: cough, shortness of breath, or chest painIntestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or have blood or mucus, or severe stomach-area (abdomen) pain or tendernessLiver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach-area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than normalHormone gland problems: headache that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, or changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulnessKidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, or loss of appetiteSkin problems: rash, itching, skin blistering or peeling, painful sores or ulcers in mouth or nose, throat, or genital area, fever or flu-like symptoms, or swollen lymph nodesProblems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with LIBTAYO. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath or swelling of ankles, confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs, double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight, persistent or severe muscle pain or weakness, muscle cramps, low red blood cells, or bruisingInfusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: nausea, vomiting, chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain, or facial swellingRejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ or tissue transplant that you have hadComplications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with LIBTAYO. Your healthcare provider will monitor you for these complications Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with LIBTAYO. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects.

Before you receive LIBTAYO, tell your healthcare provider about all your medical conditions, including if you:

have immune system problems such as Crohn’s disease, ulcerative colitis, or lupushave received an organ or tissue transplant, including corneal transplanthave received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)have received radiation treatment to your chest areahave a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndromeare pregnant or plan to become pregnant. LIBTAYO can harm your unborn baby Females who are able to become pregnant:

Your healthcare provider will give you a pregnancy test before you start treatmentYou should use an effective method of birth control during your treatment and for at least 4 months after your last dose of LIBTAYO. Talk to your healthcare provider about birth control methods that you can use during this timeTell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LIBTAYO are breastfeeding or plan to breastfeed. It is not known if LIBTAYO passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of LIBTAYO Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of LIBTAYO when used alone to treat CSCC that has spread or cannot be cured by surgery or radiation, BCC or NSCLC include tiredness, muscle or bone pain, rash, diarrhea, and low levels of red blood cells (anemia).

The most common side effects of LIBTAYO when used alone to help prevent CSCC from coming back include rash and itching.

The most common side effects of LIBTAYO when used in combination with platinum-containing chemotherapy to treat NSCLC include hair loss, muscle or bone pain, nausea, tiredness, numbness, pain, tingling, or burning in your hands or feet, and decreased appetite.

These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals at 1-877-542-8296.

Please see full Prescribing Information, including Medication Guide.  

About Regeneron's VelocImmune Technology  
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved or authorized fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo, Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.  

About Regeneron 
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Libtayo® (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (“CSCC”) at high risk of recurrence after surgery and radiation; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products (such as Libtayo) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including Libtayo for the treatment of adjuvant CSCC in the European Union, Libtayo as a monotherapy or in combination with either conventional or novel therapeutic approaches for other solid tumors and blood cancers, and Regeneron’s other oncology assets in clinical development referenced in this press release; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Libtayo) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended June 30, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Key Takeaways Astera Labs is expanding its PCIe 6 portfolio to meet the growing demand for AI infrastructure.
Amphenol's liquid cooling connectors and interconnect products are fueling strong order growth.
APH's broad market reach and 79.3% YTD gain outpace ALAB amid tougher macro conditions.

Astera Labs (ALAB - Free Report) and Amphenol (APH - Free Report) are major players in the connectivity and data center infrastructure space. While Astera Labs develops semiconductor-based connectivity solutions tailored for cloud and AI infrastructure, Amphenol specializes in interconnect and sensor technologies across diverse industries.

Per a Grand View Research report, the data center infrastructure management market was valued at around $3.06 billion in 2024 and is expected to register a CAGR of 17.3% from 2025 to 2030. Both ALAB and APH are expected to benefit from the rapid growth pace.

So, ALAB or APH — Which of these Connectivity stocks has the greater upside potential? Let’s find out.

The Case for ALABAstera Labs is rapidly expanding its portfolio to address the growing demands of AI infrastructure and connectivity solutions. It benefits from strong demand for its PCIe solutions, which is noteworthy.

ALAB’s increasing demand for AI platforms, particularly those leveraging high-performance GPUs and AI accelerators, drove strong design wins and sales for products like Aries Retimers, Taurus Smart Cable Modules and Scorpio Fabric Switches.

Expanding portfolio has been noteworthy. In 2025, Astera Labs announced that its PCIe 6 connectivity portfolio is ramping production to fast-track the deployment of modern AI platforms at scale. The offerings include new Aries 6 PCIe Smart Gearbox, Scorpio P-Series Smart Fabric Switches, Aries 6 PCIe/CXL Smart DSP Retimers, Aries 6 PCIe/CXL Smart Cable Modules (Aries 6 SCMs) and PCIe 6 over Optics Technology.

ALAB expects accelerated shipments of Scorpio P-Series switches and Aries 6 retimers on a customized rack-scale AI platform based on market-leading GPUs to boost top-line growth. Scorpio revenues are expected to account for more than 10% of total revenues in 2025, while becoming the largest product line for Astera Labs over the next several years.

The Case for APHAmphenol benefits from a diversified business model. Its strong portfolio of solutions, including high-technology interconnect products, is a key catalyst. Strong demand for high-speed and power interconnect products, which are critical components in next-gen IT systems, creates a long-term growth opportunity.

The company’s expanding portfolio has been noteworthy. In June 2025, Amphenol launched its UQD and UQDB liquid cooling connector series, designed to enhance thermal management in high-reliability systems like AI data centers, EV charging infrastructure and energy storage. Both series meet Open Compute Project standards and feature corrosion-resistant materials, leak-free seals and tool-free integration for demanding liquid-cooled environments.

APH’s strong portfolio is helping drive order growth, which jumped 36% year over year and 4% sequentially to $5.523 billion, resulting in a book-to-bill ratio of 0.98:1 in the second quarter of 2025. Amphenol’s expanding portfolio of fiber optic, power, antenna and sensor technologies continues to gain traction across datacom, aerospace and defense markets.

Price Performance and Valuation of ALAB and APHIn the year-to-date period, ALAB and APH’s shares have gained 60.2% and 79.3%, respectively. The outperformance in Amphenol’s stock can be attributed to its robust and diversified portfolio.

Despite ALAB’s strong portfolio and expanding partner base, the company is suffering from challenging macroeconomic uncertainties and stiff competition.

ALAB and Amphenol Stock Performance
Image Source: Zacks Investment Research

Valuation-wise, ALAB and APH shares are currently overvalued as suggested by a Value Score of D and F, respectively.

In terms of forward 12-month Price/Sales, ALAB shares are trading at 37.34X, higher than Amphenol’s 6.56X.

ALAB and Amphenol Valuation
Image Source: Zacks Investment Research

How Do Earnings Estimates Compare for ALAB & APH?The Zacks Consensus Estimate for ALAB’s 2025 earnings is currently pegged at $1.58 per share, which has remained unchanged over the past 30 days, indicating an 88.10% year-over-year rise.

The Zacks Consensus Estimate for Amphenol’s 2025 earnings is currently pegged at $3.03 per share, which has increased by a penny over the past 30 days, indicating a 60.32% year-over-year rise.

ConclusionWhile both ALAB and Amphenol are well-positioned to capitalize on the booming connectivity and data center infrastructure space, APH appears to be the stronger bet given its diversified revenue streams, strong order growth and broader market exposure.

Macroeconomic challenges, including higher tariffs and uncertainty over trade policy, are a headwind for semiconductor companies, including Astera Labs. These, along with changing export restrictions, are expected to negatively impact demand across the AI and cloud infrastructure markets.

Currently, Amphenol has a Zacks Rank #2 (Buy), making the stock a stronger pick than Astera Labs, which has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways AEO drives growth through digital investments, store optimization and brand expansion efforts.Aerie sales rose 3.2% in Q2 2025, with comps up 3%, reinforcing its strength in activewear.AEO plans 30 new Aerie/offline stores, 40-50 remodels and 35-40 closures to streamline operations.
American Eagle Outfitters, Inc. (AEO - Free Report) is actively executing its strategic initiatives, aimed at driving long-term growth, enhancing operational efficiency and improving agility. The company has been investing in its digital platform to grow its e-commerce business and enrich customer experience. AEO has been witnessing a spectacular response to its Aerie brand for quite some time.

The company is focused on building brand awareness and expanding into new categories. The ongoing momentum and market share growth in OFFL/NE Activewear are Aerie’s most promising long-term growth drivers.  AEO is focused on reinvigorating the brand’s growth. During the second quarter of fiscal 2025, revenues at Aerie jumped 3.2% year over year while the brand’s comparable store sales (comps) rose 3%. We expect sales for Aerie to increase 4.1% for the third quarter and 1.3% year over year for fiscal 2025.

The company is prioritizing investments across its digital channel, with foundational improvements to the shopping experience. It focuses on optimizing its store fleet to ensure the best locations, offering a seamless customer experience and tapping into additional growth opportunities. This year, the company is on track to open approximately 30 Aerie and offline locations and remodel 40-50 AE stores to feature a modern design. It anticipates shutting down 35-40 American Eagle locations by the end of the year.

The company has also been making inventory-management efforts. AEO has been navigating tariffs and implementing several mitigation strategies, involving partnering with its sourcing vendors to cut costs. Additionally, the company is diversifying its supply chain and focusing on reducing its sourcing exposure to China. It is focused on building upon its sales momentum, managing costs and making continued improvements to deliver profitability. For the third and fourth quarters of fiscal 2025, the company expects comps to rise in the low single digits.

AEO’s Price Performance, Valuation and EstimatesAmerican Eagle’s shares have lost 6.8% year to date compared with the industry’s 11.6% decline.

Image Source: Zacks Investment Research

From a valuation standpoint, AEO trades at a forward price-to-earnings ratio of 12.22X compared with the industry’s average of 17.7X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for AEO’s fiscal 2025 earnings per share (EPS) indicates a year-over-year decline of 37.4% while that of fiscal 2026 shows growth of 25.1%. The company’s EPS estimate for fiscal 2025 and fiscal 2026 has moved north in the past 30 days.

Image Source: Zacks Investment Research

American Eagle currently carries a Zacks Rank #3 (Hold).

Eye These Solid Picks in RetailLevi Strauss & Co. (LEVI - Free Report) , designer and marketer of jeans, casual wear and related accessories, currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The consensus estimate for Levi Strauss’ current financial-year EPS indicates growth of 4% from the year-ago figure. LEVI delivered an average earnings surprise of 25.9% in the trailing four quarters.

Genesco Inc. (GCO - Free Report) operates as a retailer and wholesaler of footwear, apparel and accessories, carrying a Zacks Rank #2 (Buy) at present. GCO delivered a trailing four-quarter earnings surprise of 32.4%, on average.

The Zacks Consensus Estimate for Genesco’s current fiscal-year EPS and sales indicates growth of 71.3% and 3.7%, respectively, from the year-ago period’s reported figures.

Allbirds, Inc. (BIRD - Free Report) , a lifestyle brand, currently has a Zacks Rank of 2. The company delivered a trailing four-quarter earnings surprise of 20.7%, on average.

The Zacks Consensus Estimate for BIRD’s current financial-year EPS indicates growth of 18% from the year-ago figure.

, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against C3.ai, Inc.  (NYSE: AI) ("C3.ai" or the "Company") on behalf of investors who purchased or acquired shares during the period from February 26, 2025 through August 8, 2025 (the "Class Period"),

Investor Deadline: Investors who purchased or acquired C3.ai securities during the Class Period may, no later than October 21, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE .

The lawsuit alleges that AI software company C3.ai misled investors by painting an overly optimistic picture of its growth trajectory while concealing key adverse facts, including the material impact of its CEO's health on deal execution and the Company's operational performance. On August 8, 2025, C3.ai released preliminary financial results for Q1 fiscal 2026 that fell short of expectations and lowered its revenue forecast, citing the CEO's health issues and internal restructuring. The Company's stock declined sharply in response—falling more than 25%, from a close of $22.13 per share to a close of $16.47 per share in a single trading day.

If you are a C3.ai investor and would like to learn more about this action, CLICK HERE  or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.

About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected] 

Caitlin Adorni
Berger Montague
(267) 764-4865
[email protected]

SOURCE Berger Montague

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Bloomberg's Mike McGlone reports why he is 'scared' over the price of gold. Spot gold smashed through $4,000 an ounce for the first time, as concerns over the US economy and a government shutdown added fresh momentum to a scorching rally.

Chevron CEO Mike Wirth speaks during CERAWeek in Houston, Texas, U.S., March 10, 2025. REUTERS/Kaylee Greenlee Purchase Licensing Rights, opens new tab

CompaniesHOUSTON, Oct 8 (Reuters) - Chevron

(CVX.N), opens new tab CEO Mike Wirth told employees on Wednesday that he believes the company will outperform publicly-stated financial targets given to investors following the acquisition of smaller oil producer Hess.

Upon closing the $55-billion purchase of Hess in July, Chevron said it expected $1 billion in synergies and raised free cash flow guidance for 2026 from $10 billion to $12.5 billion.

Sign up here.

"I fully expect the (Hess) deal will meet and exceed what we've committed externally," Wirth said during an internal town hall meeting, audio of which was heard by Reuters.

“Our talented workforce is an essential part of the ongoing success of our company, and we engage regularly to align on strategic priorities and our shared purpose to safely provide affordable, reliable, ever-cleaner energy that enables human progress," a Chevron spokesperson said.

Reporting by Sheila Dang in Houston;

Our Standards: The Thomson Reuters Trust Principles., opens new tab

-

NEW BRAUNFELS, Texas--(BUSINESS WIRE)--TaskUs, Inc. (Nasdaq: TASK) (“TaskUs” or the “Company”), a leading provider of outsourced digital services and next-generation customer experience to the world’s most innovative companies, today announced that at a special meeting of TaskUs stockholders, the Company did not receive the votes necessary to approve the transaction agreement with an affiliate of Blackstone, TaskUs Co-Founder and Chief Executive Officer Bryce Maddock, and TaskUs Co-Founder and President Jaspar Weir (collectively the “Buyer Group”).

TaskUs does not plan to convene another special meeting of stockholders and expects to terminate the proposed transaction. As a result, TaskUs will remain a publicly traded company, and the Company’s Class A common stock will continue to trade on Nasdaq under the ticker symbol TASK.

Maddock said, “We have appreciated the feedback received from our stockholders since our transaction announcement. We share their confidence in TaskUs and remain committed to transforming our business for the AI era.”

The final voting results from the special meeting will be reported in a Form 8-K filed by TaskUs with the U.S. Securities and Exchange Commission. Neither party will be required to pay the other a termination fee as a result of the planned mutual decision to terminate the agreement.

About TaskUs

TaskUs is a leading provider of outsourced digital services and next-generation customer experience to the world’s most innovative companies, helping its clients represent, protect and grow their brands. Leveraging a cloud-based infrastructure, TaskUs serves clients in fast-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ride-sharing, technology, financial services and healthcare. As of June 30, 2025, the Company had a worldwide headcount of approximately 60,400 people across 30 locations in 13 countries.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, and further include, without limitation, statements reflecting the Company’s current views with respect to, among other things, the Company’s operations, the Company’s financial performance, the Company’s industry, the impact of the macroeconomic environment on the Company’s business, and other non-historical statements. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “would,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates,” “position us” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to: the dependence of the Company’s business on key clients; the risk of loss of business or non-payment from clients; the Company’s failure to cost-effectively acquire new clients; the risk that the Company may provide inadequate service or cause disruptions in the Company’s clients’ businesses or fail to comply with the quality standards required by the Company’s clients under the Company’s agreements; the Company’s inability to anticipate clients’ needs by adapting to market and technology trends; utilization of artificial intelligence by the Company’s clients or the Company’s failure to incorporate artificial intelligence into its operations; unauthorized or improper disclosure of personal or other sensitive information, or securities breaches and incidents; negative publicity or liability or difficulty recruiting and retaining employees; the Company’s failure to detect and deter criminal or fraudulent activities or other misconduct by its employees or third parties; global economic and political conditions, especially in the social media and meal delivery and transport industries from which the Company generates significant revenue; the dependence of the Company’s business on its international operations, particularly in the Philippines and India; the Company’s failure to comply with applicable data privacy and security laws and regulations; fluctuations against the U.S. dollar in the local currencies in the countries in which the Company operates; the Company’s inability to maintain and enhance its brand; competitive pricing pressure; the Company’s dependence on senior management and key employees; increases in employee expenses and changes to labor laws; failure to attract, hire, train and retain a sufficient number of skilled employees to support operations; the Company’s inability to effectively expand its operations into countries or industries in which the Company has no prior operating experience and in which the Company may be subject to increased business, economic and regulatory risks; reliance on owned and third-party technology and computer systems; and failure to maintain asset utilization levels, price appropriately and control costs; the control of affiliates of Blackstone Inc. and the Company’s Co-Founders over the Company; the dual class structure of the Company’s common stock; and the volatility of the market price of the Company’s Class A common stock. Additional risks and uncertainties include but are not limited to those described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2025 and in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the SEC on August 7, 2025, as such factors may be updated from time to time in the Company’s filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the Company’s SEC filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

More News From TaskUs, Inc.

Back to Newsroom

October 08, 2025 14:49 ET

 | Source:

Critical One Energy Inc.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

TORONTO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Critical One Energy Inc. (formerly Madison Metals Inc.) (“Critical One” or the “Company”) (CSE: CRTL) (OTCQB: MMTLF) (FSE: 4EF0), a leading Canadian mining exploration company focused on critical metals and minerals, has arranged with a number of funds and high net worth investors an oversubscribed, non-brokered private placement offering of up to 7,650,000 flow-through common shares (“FT Shares”) at a price of CDN$1.00 per FT Share, for gross proceeds of up to CDN$7,650,000 (the “Offering”). 

The Company may pay a finder’s fees on a portion of the Offering to eligible finders in the form of (i) a cash commission of up to 6.0% of the gross proceeds raised under the Offering, and (ii) common share purchase warrants of the Company (“Finder’s Warrants”) in an amount up to 6.0% of the FT Shares issued under the Offering. Each Finder’s Warrant will be exercisable to purchase one common share in the capital of the Company at a price of CDN$1.50 per common share for a period of eighteen (18) months from the date of closing.

The Company intends to use the gross proceeds from the sale of the FT Shares to incur eligible “Canadian exploration expenses” that qualify as “flow-through critical mineral mining expenditures,” as defined in the Income Tax Act (Canada).

Critical One’s exploration focus is the Howells Lake Antimony-Gold Project (“Howells Lake Project”). In addition to antimony and gold, exploration will include copper, zinc, and other base metals. The Howells Lake Project is located approximately 200 kilometres from the Ring of Fire corridor in the Thunder Bay Mining Division of Ontario, Canada.

The Offering is scheduled to close on or about October 17, 2025. All securities issued pursuant to the Offering described above will be subject to a four-month and one-day hold period.

About Critical One Energy Inc.

Critical One Energy Inc. (formerly Madison Metals Inc.) is a forward-focused critical minerals and upstream energy company, powering the future of clean energy and advanced technologies. The Howells Lake Antimony-Gold Project focuses the Company’s exposure on antimony, one of the most in-demand critical minerals, as well as gold, which is known to occur at numerous locations on the Howells Lake Project. Backed by seasoned management expertise and prime resource assets, Critical One is strategically positioned to meet the rising global demand for critical minerals and metals. Its mine exploration portfolio is led by antimony-gold exploration potential in Canada and uranium investment interests in Namibia, Africa. By leveraging its technical, managerial, and financial expertise, the Company upgrades and creates high-value projects, thereby driving growth and delivering value to its shareholders.

Additional information about Critical One Energy Inc. can be found at criticaloneenergy.com and on the Company’s SEDAR+ profile at www.sedarplus.ca.

For further information, please contact:

Duane Parnham
Executive Chairman & CEO
Critical One Energy Inc.
+1 (416) 489-0092
[email protected]

Media inquiries:

Adam Bello
Manager, Media & Analyst Relations
Primoris Group Inc.
+1 (416) 489-0092
[email protected]

Neither the Canadian Securities Exchange nor CIRO accepts responsibility for the adequacy or accuracy of this release.

Forward-looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions, and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking information contained in this press release includes, but is not limited to, statements relating to the terms and timing of the private placement described in this press release and the anticipated uses of the proceeds raised from such private placement.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that: the Company will receive all necessary approval required in order to complete the issuance of the securities pursuant to the private placement described in this press release; and that there will be sufficient interest from potential investors in order to complete the private placement on the terms as described herein or at all.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, the risk that the Company will not be able to proceed with the issuance of common shares on the terms described in this press release or at all.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. The Company does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

ToplineDell’s stock reached a new all-time intraday high Wednesday, one day after the tech company nearly doubled its long-term guidance on increased demand for its data center offerings crucial to training and running artificial intelligence.

Dell boosted its guidance Tuesday. (Photo credit should read PAU BARRENA/AFP via Getty Images)

AFP via Getty Images

Key FactsDell shares were up 7.6% at $162.41 as of 2:05 p.m. EDT, the stock’s highest position of the year, and have traded as high as $166.10 on Wednesday.

The company’s stock is slated to close at an all-time high Wednesday, besting its previous all-time high of $160.18 recorded last year.

The rise in shares comes a day after Dell boosted its long-term guidance for annual revenue growth from 3-4% to 7-9% and raised its yearly earnings per share growth to 15%, up from its previous target of 8%.

Dell cited its “well positioned” portfolio that includes personal computers and data center infrastructure, the latter of which is needed to meet the operating and training needs of the AI boom.

The Nasdaq surged nearly 1% as of Wednesday afternoon, while the S&P 500 jumped a half percent.

Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you'll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here.

Crucial Quote“Customers are hungry for AI and the compute, storage and networking we provide to deploy intelligence at scale. We’re successfully translating that demand into growth and strong cash flow that we’ve largely returned to shareholders,” Dell CEO Michael Dell said in a statement.

TangentPresident Donald Trump identified Michael Dell along with billionaire media mogul Rupert Murdoch as part of the “four to five absolutely world class investors” involved in the deal to bring a portion of Chinese-owned social media app TikTok under U.S. ownership.

Key BackgroundDell’s servers and networking business jumped 69% year-over-year, according to its second quarter earnings, bringing in $12.9 billion in revenue. The company said in August it planned to ship $20 billion worth of AI servers in the upcoming fiscal year. Dell has partnered with chip designer Nvidia to help power its AI servers and has customers including OpenAI, Elon Musk’s xAI startup and cloud computing company CoreWeave. Dell also has contracts with the Energy Department (powering the agency’s next supercomputer) and G42, an AI firm based in the United Arab Emirates. Total revenue for the company reached $29.8 billion in its second quarter, a 19% increase from the same period last year.

Further ReadingOpenAI’s ChatGPT Now Connects With Third-Party Apps Like Spotify And Zillow: Here’s The Latest In The AI Arms Race (Forbes)

Key Takeaways
Nvidia CEO Jensen Huang said on Wednesday that AI demand has grown "substantially" in the last six months.The CEO also said he believes the AI boom is still in its early stages, with further room for growth.

Demand for artificial intelligence is booming and only just getting started, according to Nvidia CEO Jensen Huang.

“This year, particularly the last six months, demand of computing has gone up substantially,” the CEO told CNBC in a televised interview Wednesday, adding that that he believes the AI boom is still in its early stages, leaving room for further growth.

Shares of Nvidia (NVDA) were up 2% in recent trading, contributing to a rally in the tech sector. The chipmaker at the heart of the AI boom has seen its stock climb roughly 40% so far in 2025 as sales of its chips to power data centers surged and trade policy headwinds eased. Its move this year has helped propel Nvidia into the top spot as the world's most valuable public company, and made its CEO one of the richest people in the world.

Why This Matters for Investors
As a leading beneficiary of the AI boom, Nvidia has become something of a bellwether for the AI trade, with changes in its business and big moves in its stock able to influence broader markets.

Shares of Nvidia partners such as Micron Technology (MU) and Super Micro Computer (SMCI) also climbed Wednesday, adding to gains earlier in the week on a massive OpenAI deal with Advanced Micro Devices (AMD), which also collaborates with the companies. AMD's deal came just weeks after Nvidia announced its own deal with OpenAI.

OpenAI CEO Sam Altman said in a social media post Monday that the startup views its AMD deal as incremental to the ChatGPT maker's work with Nvidia, and that "the world needs much more compute." The move raised speculation more high-profile partnerships could be in the works, affecting a growing number of companies, with several Wall Street analysts likening the signal of strong demand for AI to a rising tide that lifts all boats.

Huang said Wednesday that his only regret is not investing more in major AI players like OpenAI and CoreWeave (CRWV), an AI data center provider in which Nvidia holds a stake.

The CEO also gave a shoutout to Tesla (TSLA) CEO Elon Musk, saying Nvidia is investing in Musk's xAI and that “almost everything that Elon is part of, you really want to be part of as well." Shares of the EV maker, which were up about 1% Wednesday, have been on a tear in recent weeks, adding roughly a third of their value since the start of September as bulls have shifted more of their focus to the company's developments in autonomous driving, robotics, and AI.

Do you have a news tip for Investopedia reporters? Please email us at

[email protected]

Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Humana (HUM) To Contact Him Directly To Discuss Their Options

If you purchased or acquired stock in Humana between July 27, 2022, to January 24, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Humana Inc. (NYSE: HUM) on behalf of long-term stockholders following a class action complaint that was filed against Humana on June 3, 2024 with a Class Period from July 27, 2022, to January 24, 2024. Our investigation concerns whether the board of directors of Humana have breached their fiduciary duties to the company.
Details:

Humana is a health insurance company that provides medical benefit plans to members.
The Humana class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that defendants downplayed pressures on Humana’s adjusted earnings-per-share resulting from increased medical costs associated with pent-up demand for healthcare procedures (especially as COVID concerns abated) which, contrary to Humana’s assurances, resulted in increased utilization rates and costs.
The Humana class action lawsuit further alleges that on June 13, 2023, UnitedHealth Group Inc., one of Humana’s principal health insurer competitors, revealed that it was seeing “higher levels” of outpatient care activity and suggested that this higher utilization was due to “pent-up demand or delayed demand being satisfied.” On this news, the price of Humana common stock fell more than 11%, according to the complaint.
Then, on June 16, 2023, the Humana class action lawsuit further alleges that Humana reported “higher than anticipated non-inpatient utilization trends, predominately in the categories of emergency room, outpatient surgeries, and dental services, as well as inpatient trends that have been stronger than anticipated in recent weeks, diverging from historical seasonality patterns.” On this news, the price of Humana common stock fell, according to the complaint.
The Humana class action lawsuit further alleges that on January 18, 2024, Humana revealed that its benefits expense ratio had increased to approximately 91.4% for the fourth quarter of 2023 and approximately 88% for the full year 2023. On this news, the price of Humana common stock fell nearly 8%, according to the complaint.
Finally, on January 25, 2024, the complaint further alleges that Humana announced a loss of $4.42 per share for the fourth quarter of 2023 that was “driven by higher than anticipated inpatient utilization . . . and a further increase in non-inpatient trends,” and stated that it expected the higher level of medical costs would “persist throughout 2024.” On this news, the price of Humana common stock fell nearly 12%, according to the Humana class action lawsuit.
Next Steps:

If you are a long-term stockholder of Humana, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com